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Introduction
There is a great need to find new therapies for the treat-
ment of breast cancer. While conventional therapies can 
extend life time in sick patients, such therapies fail to 
specifically target all cancer cells and thus are usually 
accompanied by severe side effects. An emerging new type 
of treatment is immunotherapy. Similar to a vaccine, 
immunotherapy harnesses the body’s natural defense to 
specifically recognize and kill cancer cells. This strategy 
has proven to be effective in a selected patient group 
with certain cancers such as metastatic melanoma and 
renal cell carcinoma [1, 2]. Unfortunately, breast cancer 
has not yet proven to be amenable with immunotherapy. 
It is unknown whether breast cancer is sometimes resist-
ant to such forms of therapy or whether current attempts 
of immunotherapy are not effectively been able to boost 
the natural immune system. Effective treatments have still 
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Abstract
The understanding of the molecular mechanisms of the immune tolerance 
induced by the tumoral microenvironment is fundamental to prevent cancer 
development or to treat cancer patients using immunotherapy. Actually, there 
are investigations about “addressed- drugs” against cancer cells without affecting 
normal cells. It could be ideal to find selective and specific compounds that only 
recognize and destroy tumor cells without damaging the host normal cells. For 
thousands of years, mushrooms have been used for medicinal purposes because 
of their curative properties. D- Fraction, an extract of Maitake (from the edible 
Grifola frondosa mushroom), rich in β- glucans, exert notable effects in the 
immune system. Until now, some published articles suggest that Maitake 
D- Fraction could have anti- tumoral activity, prevent oncogenesis and metastasis 
in some tumor types. However, there are no clear data about Maitake D- Fraction 
action on breast cancer prevention and its exact molecular mechanisms are not 
yet elucidated. The experiments were performed employing 25 female BALBc 
mice that were treated with and without Maitake D- Fraction Pro4X or Maitake 
Standard for 15 days by daily intraperitoneal injection. After treatment period, 
all mice were implanted with murine tumor cells LM3 to induce mammary tumo-
rigenesis. Animals were checked weekly and killed after 46 days of LM3 transplant; 
percentage of cancer prevention, rate of tumor growing, and overall survival were 
determined. Under dissection, the internal organs were evaluated histologically 
and genetically by RT- PCR. We found that 5 mg/kg per day of Maitake D- Fraction 
Pro4X, administered dairy during 15 days to BALBc mice was able to block more 
than 60% breast cancer development. However, Maitake Standard prevents onco-
genesis in 26% to respect control. In this work, we found that Maitake D- Fraction 
Pro4X, administered to BALBc mice, prevents breast carcinogenesis, block tumor 
invasiveness, reduce angiogenesis, and increase overall survival.
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not been developed to prevent tumor cells spreading from 
their primary tumor, a critical step in cancer reaching 
different organs during metastasis.
In women with high risk of breast cancer development, 
drugs such as tamoxifen and raloxifene have been used 
to reduce their risk, but those drugs shown several side 
effects [3]. Other drugs and dietary supplements that may 
help lower the risk are also being studied [4].
For thousands of years, humans have used medicinal 
mushrooms for their healing potential. A large folk tradi-
tion has passed on the knowledge of fungi from generation 
to generation, particularly in Japan and China where 
mushrooms are supported by decades of scientific research 
and are in place based firmly upon the cultural knowledge. 
The U.S. researchers have been exploring these fascinating 
organisms for their medicinal properties [5, 6]. The 
 β- glucan D- fraction of Maitake exerts profound effects 
on the immune system [7]. It is reported that the Maitake 
D- Fraction join Dectin- 1 receptors present in the outer 
membrane of macrophages and other white blood cells 
including natural killer (NK) cells and cytotoxic T (Tc) 
[8]. These immune cells are important in the protection 
and fight against cancer development, since they can attack 
tumor cells directly. Besides increasing the ability of mac-
rophages to engulf and destroy cancer cells, microbes, 
and other foreign cells, the β- glucans stimulate the pro-
duction of signaling proteins of the immune system, such 
as interleukin- 1, interleukin- 2, and cytokines [9, 10].
The β- glucans has been show anticarcinogenic activity 
and oncogenesis and metastasis’s prevention in certain 
cancer types. However, the exact mechanisms by which 
the β- glucans prevent carcinogenesis are unclear.
Our previous data support the concept that Maitake 
D- Fraction can influence the switching on and off of 
genes expressed in human breast cancer MCF- 7 cells, and 
thus could be able to control the breast cancer phenotype 
inducing apoptosis and probably involved in the reversion 
of the malignant phenotype [11].
Our objective here is to elucidated whether Maitake 
D- Fraction Pro4X, rich in beta glucans, has inhibitory 
effect against mammary tumor development, and if this 
compound is able to reduce the metastasis and invasion 




Maitake (D- Fraction) Pro4X is a product commercially 
available from Mushroom Wisdom, Inc. from NJ. (http://
www.mushroomwisdom.com). Maitake Pro4X is a purified 
extract containing 30% of active proteo beta- glucan from 
Grifola frondosa mushroom. In this work, we also used 
a crude extract from G. frondosa called Maitake Standard 
that contains 3000 mg of mushroom extract in 120 mL. 
Each bottle (60 mL) of Maitake Pro4X contains 6000 mg 
of purified D- Fraction, which is standardized to contain 
more than 1800 mg (30%) of the active proteo- glucan. 
Both, Maitake D- Fraction Pro4X or Maitake Standard 
contains no alcohol, sugar, yeast, mold, gluten, dairy foods, 
artificial colors, preservatives, or synthetic pesticides or 
fertilizers.
LM3 cell line culture
The tumor cell line LM3, derived from a murine mam-
mary adenocarcinoma in BALB/c mice, were generously 
provided by Dr. Elisa Bal- Kier Joffe from Institute of 
Oncology, Angel H. Roffo, Buenos Aires, Argentina. Cells 
were maintained in MEM medium (Invitrogen, Carlsbad, 
CA) supplemented with 5% (v/v) FBS (Invitrogen), l- 
glutamine (5 mmol/L, Invitrogen), penicillin (Invitrogen, 
100 U/mL), and streptomycin (Invitrogen, 100 μg/mL) at 
37°C in a humidified 5% CO2 air atmosphere.
Animals
In vivo experiments were carried out at the animal facility 
of BIOMED- UCA- CONICET- Buenos Aires, Argentina. 
Female BALBc mice (6–8- week- old) weighing around 24 g 
were reproduced and maintained in a climate- controlled 
room with a 12 h light/12 h dark cycle. Water and food 
were provided ad libitum. After finishing the experiments, 
animals were killed by cervical dislocation following the 
AVMA Guidelines for the Euthanasia of Animals [12].
Experiment design
The 30 female mice (6–8 weeks old) were divided into 
three groups: a control group (without Maitake) contain-
ing 10 animals, Maitake Standard Group and Maitake 
D- Fraction Pro4X group containing 10 mice each. The 
concentration used for Maitake Standard or Maitake 
D- Fraction Pro4X was 5 mg/kg, administered in a final 
volume of 40 μL diluted in PBS. The treatments were 
administered daily by intraperitoneal injection during 15 
consecutive days. Controls were injected with PBS.
Breast carcinogenesis induction
After treatment period, all mice were injected i.p. with 
4 × 105 murine tumor cells LM3 to induce mammary 
tumorigenesis. The mice were killed after 46 days of LM3 
syngeneic transplant. Under dissection, the internal organs 
were evaluated. Organs of interest such as tumors, 
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mammary gland development without visible tumor, liver, 
and lung were isolated. Half of breast tissue were keep in 
liquid nitrogen for total RNA isolation and the rest were 
placed in 10% formalin to performed histology studies.
Breast tissue examination
Animals were weekly checks by visual examination and 
palpation of abdominal- inguinal area to note tumor appear-
ance. Progressively growing masses >10 mm mean diameter 
were regarded as tumors. The tumors were measured with 
a digital caliper in two perpendicular diameters and the 
volume was calculated as (X2 × Y)/2, where X and Y 
represent, respectively, the smallest and largest diameter.
Paraffin processing of tissue
Breast tissues were sectioned for preparing paraffin blocks 
[13]. From each mouse, the tissues were drop- fixed in a 
10% formalin solution for a minimum 48 h at room 
temperature. After 48 h of fixation, tissues were moved 
into 70% ethanol. Breast tissues were dehydrated through 
a series of growing graded ethanol baths, cleared in xylene 
and embedded in paraffin. Finally, tissues were sectioned 
in 10 μm slides using a microtome.
Hematoxylin and eosin stain
The tissue architecture and ultrastructural details were 
preserved and stained with hematoxylin–eosin or periodic 
acid- Schiff staining modifications in paraffin sections [14].
Angiogenic index
In order to determine density of blood vessels in the 
paraffin blocks from mammary tissues, we did employ 
the published methodology [15]. The measure was in 
blood vessels average/mm2.
Total RNA isolation from mammary tissue
In this study, we employed frozen breast tissue (tumoral 
or normal) from each animal. The RNA was isolated by 
duplicate using Trizol (Invitrogen, Inc.) following the 
classic phenol purification method [16]. The concentration 
and the quality of total isolated RNA were measured in 
spectrophotometer considering a ratio 260/280.
RNA purification
In order to purify the total RNA isolated from each breast 
tissue, we utilized the QIAamp RNA Mini Kit from 
QIAGEN, Valencia, CA, following the author instructions. 
Briefly adding 700 μL of Buffer TW1 to the sample, cen-
trifuged at 8000g during 15 sec at room temperature, 
discarded the flow trough, change the tube and washed 
RNA adding 500 μL of Buffer RPE twice, centrifuged at 
8000g during 15 sec at room temperature, discarded the 
flow trough. A new microtube was placed and 30 μL of 
free RNases water was added, and centrifuged at 10,000g 
for 1 min. The eluted RNA was collected and its con-
centration was measured using spectrophotometer at 
260 nm, and before amplification by RT- PCR, an 1% 
agarose gel was run to visualize its quality.
Reverse transcription (RT) reaction
The RT reaction contained 1 μg of purified total RNA, 
5 μL of Buffer M- MLV 5X (Promega, Madison, WI), 
10 mmol/L each of dATP, dGTP, dCTP, dTTP, 0.5 mg/
mL OligodT primer, and 1 μL of M- MLV RT enzyme 
(Promega). A 10 μL mixture of total RNA and primer 
was heated for 5 min at 70°C, cooled on ice at least 
2 min, and quickly spun before adding the remaining 
components (final volume 20 μL). The reaction proceeded 
for 1 h at 40°C and was terminated by heat inactivation 
at 70°C for 15 min. RT products were stored at −20°C 
until used.
Polymerase chain (PCR) reaction
The nucleotide sequence of each primer used in this work 
is indicated in Table 1. Each reaction (PCR) was performed 
following the established Protocols [17], briefly using 50 ng 
of cDNA, 1X PCR Buffer with 1.5 mmol/L MgCl2 
(Amersham Biosciences, Piscataway, NJ), 200 μmol/L 
dNTPs (Amersham Biosciences), 10 μmol/L of each primer 
(see Table 1), and 1 U Taq DNA polymerase (Amersham 
Biosciences) in a final volume of 12.5 μL. The PCR pro-
tocol was the same for each amplified gene region except 
for the annealing temperature which was specified by each 
primer pair. The amplification conditions were: 5 min 
initial denaturalization at 94°C, 35 cycles of 30 sec at 
94°C, 60 sec at the annealing temperature (annealing) of 
each pair of primers and 30 sec elongation at 72°C. Followed 
by a final extension of 10 min at 72°C and maintained 
at 4°C until removal from the thermocycler samples.
PCR products visualization and 
semiquantification
To visualize the amplified RNAs, samples were run in 3% 
Agarose gel at 120 V during 40 min and stained with 
ethidium bromide and visualized in Benchtop 2UV tran-
siluminator (Bio DOC- It Imaging System; UVP, LLC Ultra-
Violet Products Ltd, Upland, CA). Semiquanti fication was 
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done using the densitometric analysis using NIH Image 
(http://rsb.info.nih.gov/nih-image).
Statistics analysis
The effect of treatment was tested by ANOVA [18]. 
Differences among means were assessed using Student’s 
t- tests. Experiments were done by triplicate as independ-
ent experiments. Variability was expressed as SE. Differences 
were considered significant at P < 0.05. Kaplan–Meier 
survival curves and the log- rank test were used to analyze 
the differences between the two groups (Maitake Standard 
and Maitake Pro4X) with respect to control.
Results
Effect of Maitake D- fraction Pro4X in the 
breast cancer prevention
In order to demonstrate if the purified extract Maitake 
D- Fraction Pro4X has an effect in the breast cancer pre-
vention; three independent experiments were done employ-
ing female nulliparous Balbc mice. Figure 1 shows a 
representative picture of mice abdominal area from each 
condition after 30 days of tumor challenge. From this 
experiment, we observed 100% of breast tumorigenesis 
(10 out 10 animals) in the control group. Five out 10 
animals treated with 5 mg/kg of Maitake Standard 
(Standard) developed breast tumor. However, only three 
out 10 mice developed mammary tumors in the condition 
treated with purified extract Maitake D- Fraction Pro4X 
(Pro4X) (Fig. 1).
The average from three independent experiments of 
prevention against breast tumorigenesis development in 
animals from Control group was 3.333 ± 5.774 (Fig. 2), 
which was significantly different from the prevention gen-
erated by Pro4X (64.286 ± 23.862, P < 0.01) and also 
were different from those results obtained from employing 
Standard (26.429 ± 16.335, P < 0.05) as well (Fig. 2).
Effect of Maitake D- fraction Pro4X in the 
tumor grows that escape to treatment
After analyzing the prevention percentage in each treat-
ment, it is important to study the tumor growth curve 
that did not respond to Maitake treatment and escaped 
its control. From Figures 1, four out 10 and three out 
10 animals escaped the Maitake Standard and Pro4X pre-
vention, respectively and developed breast tumors. If the 
tumor area is comparable between groups, we are looking 
for to study even those events. Figure 3A indicated the 
mammary tumor growing curve (longitudinal size in cm) 
in each mouse with breast tumors from each group since 
7–24 days after tumor challenge. From the graphic, it 
was observed that breast tumor in the animals from con-
trol group grew linearly since 10–24 days after tumor 
challenge; however, the breast tumorigenesis after Pro4X 
treatment did grow slowly at the same time and at 24 days, 
achieved a similar size compare to the Standard treatment 
(See Fig. 3A). In the Standard treatment, the tumor grows 
curve was significantly different (*P < 0.05) to compare 
with Control until day 20; however, after 22 days, the 
tumor grew in a similar size as the group without Maitake 
(Fig. 3A). At 46 days, after tumor challenge (the end of 
experiment), the tumor area (cm2) did not achieve any 
significant difference between groups.
From another side, it was found macroscopic differences 
in the breast tumor between groups. At 46 days after tumo-
rigenesis, challenge was observed that breast tumors without 
Maitake (control) were solid and with irregular edges; how-
ever, tumors from Maitake Pro4X were same size than con-
trols but full of liquid, not solid, with net tumor round 
edges (Fig. 3C). Tumors from Maitake Standard treatment 
showed a macroscopic aspect similar to control.
Table 1. Nucleotide sequence of forward and reverse primers to amplify ABCG2, CUL3, IGFBP5, PTEN, and SPARC genes by RT- PCR method.
Primer Nucleotide sequence 5′→3′ Tm (°C) Size of fragment (bp)
β- Actin forward primer GGATGCAGAAGGAGATCACTG 60.0 90
β- Actin reverse primer CGATCCACACGGAGTACTTG
ABCG2 forward primer GCTGTGGAGCTGTTCGTAGT 61.8 664
ABCG2 reverse primer AGTCCGTTAAAGGGGGAAATTAAGA
CUL3 forward primer TCCCCAGGTCTTCAGTGTTGA 62.5 884
CUL3 reverse primer TTGGAAGCACAGAGGAACGG
IGFBP5 forward primer CAGTATACCCATCACCCCGC 63.4 989
IGFBP5 reverse primer ACAGCTGACCTCCTCCGTAT
PTEN forward primer GTGGTCTGCCAGCTAAAGGT 62.4 1000
PTEN reverse primer AAGTGCAAAGGGGTAGGACG
SPARC forward primer TCTGGGTAGCACACAGCCTA 62.4 951
SPARC reverse primer TCTCAAAGTCTCGGGCCAAC
β- Actin amplification was used as control.
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Figure 1. Photographs of the abdominal region of 30 BALBc mice in the Control, Maitake Standard, and Maitake Pro4X groups. After 15 days of 
treatment with each compound in a concentration of 5 mg/kg, breast tumorigenesis was implanted in mice peritoneal region as indicated in 
Methodology and breast tumorigenesis were checked by weekly. Red arrows indicate the breast tumor in each mouse. *P < 0.01.












Figure 2. Breast cancer prevention induces by Maitake. This figure indicates the average results obtained from three independent experiments. 





























Experiment 1 Experiment 2 Experiment 3 Average S.D.
Control 0.0 10.0 0.0 3.333 5.774
Standard 45.0 14.3 20.0 26.429 16.335
Pro4X 90.0 42.9 60.0 64.286 23.862
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Effect of Maitake D- fraction Pro4X in the 
histology of breast cancer developed
The differences found in the macroscopic aspect of tumors 
treated with or without Maitake address us to perform 
histology studies from mammary tissue, paraffin blocks 
were performed, 5 mm slides were stained with H&E and 
observed with optical microscope. The histology slides of 
mammary tissues from each treatment group with and 
without Maitake are illustrated in Figure 4. The last figure, 
Normal breast represents the breast tissues without tumors 
developed after Maitake Pro4X treatment. The histology 
studies from mammary tumors indicated that breast tumors 
from Control group corresponded to hyperplasic and 
poorly differentiated breast tissue comparable with invasive 
cancer. Breast tumors treated with Maitake Standard were 
found similar to control group; however, mammary tumors 
treated with Maitake Pro4X were histologically differenti-
ated from other groups, were well differentiated, not 
invasive with net borders, and less number of cells com-
parable to a benign breast tumor (Fig. 4). These surprising 
results address us to think that Maitake Pro4X could be 
Figure 3. Breast tumorigenesis grows. (A) Growing curves from 7–24 days after tumor bearing in mice treated and untreated with Maitake Standard 
or Pro4X, respectively. (B) The abdominal area of representative’s mice from each condition at 10, 14, 20, and 24 days after tumorigenesis initiation. 
In the pictures, the red arrows indicate the presence of breast tumors. (C) Pictures of breast tumor from a representative mice from each group. In 
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avoiding the metastasis process in organs such as lung 
or liver. We next evaluated metastasis.
Effect of Maitake Pro4X on tumor necrosis
Another aspect that is important to analyze in this work 
is the appearance of necrosis in the developed breast tumors. 
Figure 5A shows the macroscopic aspect of breast tumors 
with and without Maitake at 46 days after tumor challenge. 
After measuring the necrosis area (cm) from breast tumor 
in each animal group (Fig. 5B), it can be concluded that 
control developed breast tumors with higher necrosis area 
compared to Maitake Standard (*P < 0.05) or Maitake 
Pro4X (*P < 0.01). The treatment with Pro4X practically 
did not developed necrosis in their tumors (Fig. 5).
Effect of Maitake Pro4X on metastasis in 
liver and lung tissues
In order to verify the presence or absence of metastasis, 
lung and liver were isolated from each tumor- bearing 
mice treated with or without Maitake Standard or Maitake 
Pro4X. Weigh, macroscopic aspect, and size of lung and 
liver from those mice were checked.
The lung and liver average area (cm2) from each 
experimental group were analyzed. No significant differ-
ences in sized of lung or liver tissues from all animals 
in each experimental group were found (data not shown). 
But nevertheless, macroscopically, liver tissues from 
Control Group were completely different from those 
treated with Maitake (Fig. 6A). The mice’s liver without 
Maitake treatment were colorless and rigid, with signs 
of metastasis (indicated with red arrow in Fig. 6A right). 
Liver tissue histology from tumor- bearing mouse in the 
control group showed and confirmed cell proliferation 
and the hyperplasia (Fig. 6A left). However, liver tissues 
from Maitake Standard (Fig. 6C) or Pro4X (Fig. 6B) 
treated were darker, with texture and aspect normal. In 
the Standard treatment, histology was observed in few 
regions of the liver tissue with hyperplasia and prolifera-
tion that was not significant compared to control. 
Figure 6D shows a normal liver tissue from animals 
Figure 4. Histology of mammary tissues from each treatment group with or without Maitake. The picture indicated as normal breast corresponded 
to breast tissues without tumor developed after Maitake Pro4X treatment. Right picture shows the paraffin block of breast tissues, the arrow indicate 
the amplified region and left picture shows the corresponding microscopy breast histology.
Control Standard
Maitake Pro4X Normal Breast
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without breast tumor that resist carcinogenesis after Pro4X 
treatment. The histology studies from liver tissues indi-
cated that the mice from control group have a liver tissue 
with bigger blood vessels, with liver structure different 
than normal and some mitotic changes. However, the 
liver tissues treated with Maitake Pro4X were not found 
different than normal liver tissue.
In the macroscopic studies of lung tissues, we did not 
observe morphological differences between tumor- bearing 
mice and non- tumor- bearing mice. However, surprisingly, 
were observed higher mitosis percentage in the lung histol-
ogy sections from animals in the control group (7.50 ± 0.7) 
compared to Maitake treatments (0.8 ± 0.1, P < 0.05 in 
the Standard and 0.1 ± 0.02, P < 0.001 in the Pro4X) 
(Fig. 7A). Black arrow indicated in Figure 7B shows the 
mitosis in the bronchiolar area from lung tissue corre-
sponding to each group of treatment. No statically differ-
ences were observed between percent of mitosis in both 
Maitake treatments compared to normal lung tissue.
Effect of Maitake extract in the 
angiogenesis process
The Angiogenic index in the tumoral breast tissues was 
measured in order to establish if Maitake D- Fraction Pro4X 
are able to exert an antiangiogenic effect. Figure 8A shows 
the graphics of average of blood vessels density in each 
group. Figure 8B shows the pictures of breast tumors 
from the treatment groups a, control; b, Standard and 
c, Pro4X, respectively. From Figure 8, it was observe that 
the blood vessels number/mm2 in breast tumor tissues 
from Control Group mice (0.637 ± 0.182) were signifi-
cantly higher (P < 0.05) than breast tumors treated with 
Maitake Standard (0.339 ± 0.149) or than Maitake Pro4X 
treatment (0.031 ± 0.028). Figure 8B shows the slide sec-
tions from breast tumors analyzed. Black arrows indicated 
the size and location of blood vessels in each tissue.
Effect of Maitake extract in the relative 
overall survival in BALBc mice
The overall relative survival in the mice from each group 
of treatment were analyzed using Kaplan–Meier curves 
since the beginning to the end of the experiment at 
46 days after tumorigenesis initiation (Fig. 9). From those 
curves, it was observed that since 35 days to the end, 
the overall survival were significantly different between 
Maitake treatments (1.00 ± 0.00, both Standard and Pro4x) 
compared to control group (0.87 ± 0.086). From this 
time, survival decreases more rapidly in control compared 
Figure 5. Maitake Pro4X treatment reduces tumor necrosis. In (A), represents the pictures of breast tumors isolated (left) and in vivo (right) in all 
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Figure 6. (A–D) The liver tissues histology (left) of tumor- bearing mice from Control, Maitake Pro4X, Maitake Standard, and the normal liver from 
animals without breast tumor that resist carcinogenesis after treatment with Maitake Pro4X, respectively. Black arrows represent the cell proliferation 
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Figure 7. Study of mitogenesis in lung tissues. In (A) represents the % of mitosis in lung tissue at each condition. *P < 0.05, and **P < 0.01. (B) The 
pictures from the histology of lung tissue in every group: Control, Standard and Pro4X. The right pictures represent a magnification of left image at 
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to Standard. At the end, at 46 days after tumor challenge, 
the overall survival is reduced to 0.108 ± 0.099 in Control, 
which was significantly different compared to Standard 
(0.82 ± 0.12, P < 0.05) or Pro4X (1.00 ± 0.00, P < 0.01) 
(Fig. 9). Overall survival in Pro4X decreases to half at 
50 days after tumor challenge.
Figure 8. (A) The graphics of average of blood vessels density/mm2 in each group. (B) shows the pictures of breast tumors analyzed, Black arrows 





































Figure 9. Kaplan–Meier overall survival curves. The graphic represents of overall relative survival from 7 to 50 days after tumorigenesis initiation. 
A green line represents the control group, a blue line represents the Standard treatment, and a red line indicates the survival after Maitake Pro4X 
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Effect of Maitake PRO4X on specific gene 
expression related to tumoral phenotype 
inhibition
With the objective to determine if Maitake D- Fraction 
PRO4X modifies the gene expression of tumoral phenotype, 
total RNA was isolated from all breast tumors of experi-
mental groups and from the mammary glands of non- 
tumor- bearing mice from Maitake Pro4X treatment. 
ABCG2, CUL3, IGFBP5, PTEN, and SPACR gene expres-
sions were modified after Maitake treatment in MCF- 7 
cells as were previously published by us [11]. Figure 10A 
shows the RT- PCR bands in the agarose gels from each 
of those genes in breast tumors after treatment with or 
without Maitake. The last column represents the breast 
tissues treated with Maitake Pro4X without tumor indicated 
as Normal breast Pro4X in the Figure 10A. Beta actin 
gene expression was used as control. This study showed 
that SPARC gene was differentially expressed in all the 
tumor conditions. SPARC gene expression was up- 
modulated in the breast tumor tissues treated or untreated 
(control, 33.5 ± 0.70) with Maitake Standard (43.0 ± 0.90) 
or Pro4X (37.25 ± 0.70) (Fig. 10B). A clear down- 
modulation (5.0 ± 0.01, P < 0.01) was observed in SPARC 
gene expression from normal breast tissues after Pro4X 
treatments that were resistant to carcinogenesis.
With respect the gene expression of PTEN, similar level 
of mRNA was observed for control (65.00 ± 1.30), Standard 
(75.0 ± 1.50), or Pro4X (62.5 ± 1.30) in breast tumors 
(Fig. 10A and B). However, PTEN gene expression was 
significantly down- modulated in normal breast tissues 
treated with Pro4X (7.0 ± 0.20, P < 0.01).
ABCGs gene are also expressed differentially in breast 
tumors compared to normal breast tissue after Pro4X 
treatment. ABCGs gene expression were not significantly 
different in control (45 ± 0.90), compared to Maitake 
treatment (Standard, 50.0 ± 1.00 or Pro4X, 47.5 ± 1.00) 
in breast tumors. However, a significant down- modulation 
was observed (20 ± 0.50, P < 0.05) in normal breast 
tissues resistant to carcinogenesis after Pro4X treatment 
(Fig. 10A and B).
Moreover, CUL3 and IGFBP5 gene expression analysis 
did not show a significant difference between tumors or 
normal tissues. CUL3 and IGFBP5 genes were expressed 
in all conditions at same level (Fig. 10A and B).
Discussion
The antitumor properties of Maitake D Fraction are attrib-
uted to its immunomodulatory effect. However, a direct 
effect of Maitake on prostate cells [19], stomach [20], 
kidney [16] and breast cancer [21] by inducing apoptosis 
has also been reported.
The potential effects of various natural compounds such 
as herbs and dietary supplements are investigated to reduce 
the risk of cancer. It has been reported that β- glucans 
of Maitake possess the ability to inhibit tumor growth 
administered either orally or intraperitoneally [22]. In this 
work, the effects of a purified extract of Maitake D- Fraction 
and Pro4X were investigated in comparison with the crude 
Figure 10. Gene Expression analysis. (A) The gene expression at mRNA level in all the conditions. (B) Relative quantification of each RT- PCR reaction. 
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extract of G. frondosa, edible mushroom called Maitake 
Standard in the prevention of mammary tumorigenesis 
in BALBc mice. Therefore, they are essential in the future 
to isolate and chemically characterize (determine the com-
position and structure) the active components of both 
Maitake Standard and D- Fraction Pro4X.
The results suggest that 5.0 mg/kg of Maitake D- Fraction 
Pro4X prevents mammary tumorigenesis in more than 
64% in BALBc mice by intraperitoneal injection, compared 
to Maitake Standard prevention that achieve an average 
of 26.43%. Concluding from those results that Maitake 
Pro4X has a significant effect on the prevention of breast 
carcinogenesis compared to Maitake Standard. Similar 
results were obtained by Nanba and Kubo [23], whom 
treated BALBc mice with 0.2 mg of Maitake D Fraction 
for 15 consecutive days, and after tumorigenesis induction 
with carcinogen 3- methylcholanthrene, they obtained about 
69% inhibition of hepatic carcinogenesis (compared with 
7% in the control group).
Those results can be explained considering that Maitake 
Standard product is a nonpurified D fraction, and may 
contain other components than 1,3 or 1,6 beta glucans, 
the known active compounds responsible for the thera-
peutic actions in breast cancer. Studies to date have iden-
tified a number of compounds and elucidated underlying 
mechanism. However, research is needed to elucidate the 
different roles of multiple active compounds and the 
pathways involved.
In addition to preventing mouse breast carcinogenesis, 
Maitake Pro4X significantly reduces tumor necrosis and 
aggressiveness compared to untreated condition, suggest-
ing that this compound is also involved in the reduction 
of invasiveness and metastasis. The inhibition of metastasis 
is the key for delaying cancer progression and prolonging 
patient’s survival. In previous studies, using mice, several 
authors have reported the ability of Maitake D- Fraction 
to prevent the liver [24] and lung [8] metastases devel-
opment. It has been suggested that the mechanism involved 
the activation of the immune system, which facilitates 
the elimination of tumor cells in the blood or lymphatic 
circulation. In this work, the liver and lung tissues from 
Maitake- treated and - untreated mice were checked to 
verify the presence or absence of metastases in these 
organs. Concerning to liver tissue, differences between 
groups were observed. In the control group, dilated ves-
sels and liver tissue with abnormal structures were 
observed. Instead, the treated groups with Maitake 
Standard or Pro4X did not show morphological differ-
ences compared to normal tissues. We observed that 
maitake treatment significantly reduce the cell prolifera-
tion and percentage of mitosis in lung tissue compared 
to untreated condition. However, further studies are 
needed to determine with certainty whether histological 
abnormalities of the control animals are due to 
metastasis.
Angiogenesis is a fundamental process in tumor growth 
and metastasis generation. The results obtained in this 
work suggest that density of blood vessel was significantly 
lower in treated groups with both Maitake Standard and 
Pro4X with respect control group; moreover, the lowest 
blood vessel density corresponded to Maitake Pro4X- treated 
group. These results are in agreement with a previous 
study which showed that an aqueous extract of Maitake 
inhibited the in vivo or in vitro VEGF induced angio-
genesis both in vitro and in vivo [25]. Regarding the 
histology of the mammary tissues, it is important to note 
that mammary tumors treated with Maitake Pro4X have 
decreased proliferation and increased differentiation com-
pared to control group. This is consistent with the idea 
that Maitake D Fraction could help to reduce the process 
of mammary carcinogenesis and tumor progression.
Despite advances in the treatment of breast cancer, 
there are still many obstacles to overcome. In many cases, 
the treatment is ineffective due to resistance of tumor 
treatment or due to the presence of metastases. Moreover, 
existing therapies can produce adverse side effects due to 
their specificity. For these reasons, new research and care-
fully look more lenient to treat cancer patients are need 
it, inhibiting metastasis, increasing survival and improving 
life quality. Our results shown that 5 mg/kg of Maitake 
treatment increases significantly the overall survival from 
10% in the control to more than 75% at 46 days after 
tumor challenge. Extrapolating with human life time, 
46 days represents more than 10 years in human, mean-
ing that, this natural and purified compound could poten-
tially increase the overall survival of more than 10 years 
in untreated patients with high grade of breast cancer.
Later studies were performed to determine whether the 
administration of Maitake Pro4X- modulated gene expres-
sion on breast tumor tissue. ABCG2, Cul3, IGFBPR5, 
PTEN, and SPARC genes levels of expression were related 
to the malignant phenotype in tumor cells, and those 
differential expressions were found to be modulated by 
Maitake in our previous studies [11].
One of the genes analyzed was secreted protein, acidic, 
cysteine- rich (osteonectin) (SPARC), whose role in mam-
mary carcinogenesis and metastasis is controversial. Some 
studies have linked high basal expression of SPARC with 
a poor prognosis and decreased survival in breast cancer 
patients with HER2+ [26], invasive ductal carcinoma [27], 
and a shorter time to recurrence in patients with ductal 
carcinoma in situ [28]. It has also reported the absence 
of SPARC expression in benign tumors [27]. On the other 
hand, SPARC have been associated with low expression 
and decreased survival in poor prognosis patients with 
luminal subtypes A or triple negative breast tumors [29]. 
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It has also been reported that its endogenous up- modulated 
expression in cells of breast cancer MDA- 231 cells are 
related to reduce metastases and reduce invasiveness activ-
ity [30]. In this work, it was found that SPARC gene is 
little or not expressed in the normal breast tissue resistant 
to breast carcinogenesis, from mice treated with Maitake 
Pro4X, whereas SPARC was highly expressed in breast 
tumor tissues. These results are in agreement with the 
work of Watkins et al. [31] who reported higher levels 
of SPARC gene in breast tumor tissue compared to normal 
breast tissue. Suggesting that Maitake D- Fraction Pro4X 
could contribute to maintain the down- modulated SPARC 
gene expression to prevent breast carcinogenesis. However, 
when the SPARC inhibition threshold induced by Maitake 
is overcome, breast cancer will be developed without 
SPARC control. Moreover, we can hypothesize here that 
Maitake D- Fraction Pro4X could induce prevention against 
breast carcinogenesis through down- modulation of mRNA 
SPARC gene expression level.
Phosphatase and tensin homolog (PTEN) was reported 
as a tumor suppressor gene that negatively regulates onco-
genic pathway of phosphatidylinositol- 3- kinase (PI3K)/Akt 
[32], was also found mutated in various cancers and its 
expression has been associated with tumor progression 
in a dose- dependent fashion [33]. In this work, it was 
found that PTEN gene was not expressed in normal breast 
tissue corresponding to a breast carcinogens- resistant tis-
sue. Moreover, here, it was found that PTEN gene was 
overexpressed in breast tumor tissues, treated or untreated 
with Maitake. This data could suggest that probably PTEN 
is shown up- modulated due to a mutation and its accu-
mulation in breast cancer tissue, however, in the normal 
breast tissue, the tumor suppressor PTEN are not expressed 
or is down- modulated due to nonmutation and nonac-
cumulation. These results suggest that the PTEN promoter 
gene variation in expression could have an effect on 
increased metastatic potential and progression of the tumor. 
Concluding that Maitake Pro4X could regulate the expres-
sion of the PTEN gene involved in breast carcinogenesis. 
However, further studies will be needed to determine the 
exact role of functional PTEN variant proteins.
Cullin 3 (Cul3) gene expressions was also studied in 
breast tumors from Maitake- treated and - untreated mice. 
Cul3 plays an important role in protein degradation by 
the proteasome [34]. Cul3 loss expression has been detected 
in a wide range of human liver cancers and correlated 
directly with tumor de- differentiation [35]. Recently, Cul3 
gene expression level was correlated with tumor stage in 
breast tissues [34]. Also, Cul3 has been involved in the 
ubiquitination of breast cancer metastasis suppressor 1 
gene (BRMS1), which inhibits metastasis [36]. In this 
study, no differences in Cul3 gene expression in mam-
mary tissues with or without tumor, Maitake treated or 
untreated were observed; so that it cannot be associated 
with the expression level in the tumorigenesis process.
ABCG2 is involved in multidrug resistance in breast 
tumors [37–40]. Specifically carries different chemothera-
peutic agents and is involved in the development of mul-
tiple drug resistance in cancer cells. Increased ABCG2 
gene expression has been reported in Mitoxantrone- 
resistant breast cancer cell line with respect to a sensitive 
Mitoxantrone MCF- 7 cell line [40]. The results in this 
work indicate that ABCG2 gene is not expressed or is 
slightly expressed in normal breast tissue resistant to car-
cinogenesis induced by Maitake, but is expressed in breast 
tumors treated or untreated with Maitake, suggesting 
probably that ABCG2 gene expression could have a com-
plementary role involved the oncogenesis de- differentiation, 
meaning that when is over- expressed, increases the tumo-
rigenic potential of transformed cells, and the resistance 
to multidrugs, as occuring in the breast tumors treated 
or untreated with Maitake. However, when ABCG2 is 
slightly expressed or not expressed, directly or indirectly 
inhibited the oncogenesis and reduce the tumorigenic 
potential of tumoral cells, and maintain the threshold of 
tumorigenesis low, or inhibited as happen with the breast 
tissue without tumor which was resistant to carcinogenesis 
after treatment of Maitake Pro4X. The question is why 
Maitake Pro4X did not protect 100% of animals against 
breast cancer development? To answer this question, we 
need to continue to investigate whether the oncogenesis 
protection mediated by Maitake Pro4X is related to the 
environmental exposure and the level of effectors’ immune 
response in each individual.
Finally, the expression of IGFBP5 gene was studied. It 
has been shown that IGFBP5 prevents cell growth of 
human breast cancer either in vitro or in vivo, causing 
G2/M cell cycle arrest and induction of apoptosis associ-
ated with increased mRNA expression of pro- apoptotic 
BAX, and decreased expression of antiapoptotic BCL- 2 
[41]. In an in vitro assay, a reduction of IGFBP5 gene 
expression in human breast cancer MCF7 Tamoxifen- 
resistant cells was also observed [42]. In this work, no 
difference was observed in the IGFBP5 gene expression 
between tumor and normal breast tissue treated or 
untreated with Maitake, so it can not establish a relation-
ship between Maitake treatment and the expression of 
this gene and development of breast tumorigenesis in vivo. 
No differences between tumors from Maitake treated and 
untreated were observed; so, in conclusion, Maitake 
D- Fraction did not exert an effect on the expression of 
IGFBP5 gene in breast tumorigenesis in BALBc mice model.
In conclusion, in this work, we demonstrated that 
intraperitoneal administration of 5 mg/kg Maitake 
D- Fraction Pro4X during 15 days prevents breast tumo-
rigenesis in more than 60%, increases the overall survival 
2440 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
A. Roldan- Deamicis et al.Maitake Pro4X and Breast Cancer Prevention
from 10 to 75%, reduces angiogenesis process, and protects 
against lung and liver metastases in female BALBc mice. 
However, the active molecule from the Maitake Pro4X 
extract and which is the exact molecular mechanism to 
be utilized to act as tumor preventive agent are needed 
to be determined. Base upon of these results, we can 
postulated a Maitake D- Fraction Pro4X as a good can-
didate to be used as preventive agents in breast carcino-
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